Photosensitizer

This page covers all Photosensitizer drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Protoporphyrin IX (endogenous photosensitizer generated from ALA), Porphyrin-based photosensitizer (non-receptor mediated), Hypericin (photosensitizing agent); generates ROS upon light activation.

Targets

Protoporphyrin IX (endogenous photosensitizer generated from ALA) · Porphyrin-based photosensitizer (non-receptor mediated) · Hypericin (photosensitizing agent); generates ROS upon light activation · protoporphyrin IX (PpIX)

Marketed (3)

• aminolevulinic acid (ALA) · University of California, Davis · Oncology
  Aminolevulinic acid is a precursor to protoporphyrin IX, which accumulates in cells and generates reactive oxygen species when activated by light, enabling photodynamic therapy.
• Rose Bengal · University of California, San Francisco · Oncology
  Rose Bengal is a xanthene dye that generates reactive oxygen species upon light activation to destroy targeted cells and tissues.
• Hemoporfin PDT · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Oncology
  Hemoporfin is a photosensitizer that generates reactive oxygen species upon light activation to destroy tumor cells in photodynamic therapy.

Phase 3 pipeline (2)

• padeliporfin VTP · Steba Biotech S.A. · Oncology
  Padeliporfin VTP is a photosensitizer that selectively targets and destroys cancer cells upon activation by light.
• SGX301 (synthetic hypericin) · Soligenix · Oncology; Dermatology
  SGX301 is a synthetic hypericin that generates reactive oxygen species upon light activation to destroy targeted cells, particularly in photodynamic therapy applications.

Phase 2 pipeline (2)

• BF-200 ALA 1% · Biofrontera Bioscience GmbH · Dermatology
  BF-200 ALA 1% is a topical photosensitizer that, when activated by light, generates reactive oxygen species to induce cell death in targeted tissues.
• Aminolaevulinic acid photodynamic therapy · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Oncology
  Aminolaevulinic acid acts as a precursor to porphyrin, which accumulates in cancer cells and is activated by light to produce reactive oxygen species, inducing cell death.